TY - JOUR
T1 - Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy
AU - Seferović, Petar M.
AU - Tsutsui, Hiroyuki
AU - McNamara, Dennis M.
AU - Ristić, Arsen D.
AU - Basso, Cristina
AU - Bozkurt, Biykem
AU - Cooper, Leslie T.
AU - Filippatos, Gerasimos
AU - Ide, Tomomi
AU - Inomata, Takayuki
AU - Klingel, Karin
AU - Linhart, Aleš
AU - Lyon, Alexander R.
AU - Mehra, Mandeep R.
AU - Polovina, Marija
AU - Milinković, Ivan
AU - Nakamura, Kazufumi
AU - Anker, Stefan D.
AU - Veljić, Ivana
AU - Ohtani, Tomohito
AU - Okumura, Takahiro
AU - Thum, Thomas
AU - Tschöpe, Carsten
AU - Rosano, Giuseppe
AU - Coats, Andrew J.S.
AU - Starling, Randall C.
N1 - Publisher Copyright:
© 2021 Elsevier Inc. and Journal of Cardiac Failure. [Published by Elsevier Inc.] All rights reserved.
PY - 2021/6
Y1 - 2021/6
N2 - Endomyocardial biopsy (EMB) is an invasive procedure, globally most often used for the monitoring of heart transplant (HTx) rejection. In addition, EMB can have an important complementary role to the clinical assessment in establishing the diagnosis of diverse cardiac disorders, including myocarditis, cardiomyopathies, drug-related cardiotoxicity, amyloidosis, other infiltrative and storage disorders, and cardiac tumours. Improvements in EMB equipment and the development of new techniques for the analysis of EMB samples have significantly improved diagnostic precision of EMB. The present document is the result of the Trilateral Cooperation Project between the Heart Failure Association of the European Society of Cardiology, the Heart Failure Society of America, and the Japanese Heart Failure Society. It represents an expert consensus aiming to provide a comprehensive, up-to-date perspective on EMB, with a focus on the following main issues: (i) an overview of the practical approach to EMB, (ii) an update on indications for EMB, (iii) a revised plan for HTx rejection surveillance, (iv) the impact of multimodality imaging on EMB, and (v) the current clinical practice in the worldwide use of EMB.
AB - Endomyocardial biopsy (EMB) is an invasive procedure, globally most often used for the monitoring of heart transplant (HTx) rejection. In addition, EMB can have an important complementary role to the clinical assessment in establishing the diagnosis of diverse cardiac disorders, including myocarditis, cardiomyopathies, drug-related cardiotoxicity, amyloidosis, other infiltrative and storage disorders, and cardiac tumours. Improvements in EMB equipment and the development of new techniques for the analysis of EMB samples have significantly improved diagnostic precision of EMB. The present document is the result of the Trilateral Cooperation Project between the Heart Failure Association of the European Society of Cardiology, the Heart Failure Society of America, and the Japanese Heart Failure Society. It represents an expert consensus aiming to provide a comprehensive, up-to-date perspective on EMB, with a focus on the following main issues: (i) an overview of the practical approach to EMB, (ii) an update on indications for EMB, (iii) a revised plan for HTx rejection surveillance, (iv) the impact of multimodality imaging on EMB, and (v) the current clinical practice in the worldwide use of EMB.
UR - http://www.scopus.com/inward/record.url?scp=85106338634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106338634&partnerID=8YFLogxK
U2 - 10.1002/ejhf.2190
DO - 10.1002/ejhf.2190
M3 - Article
C2 - 34010472
AN - SCOPUS:85106338634
SN - 1388-9842
VL - 23
SP - 854
EP - 871
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 6
ER -